SION-719 Misses CFTR-Activity Endpoint in Phase IIa
Sionna Therapeutics reported that adding the NBD1 stabilizer SION-719 to Trikafta for 14 days did not achieve the Phase IIa trial’s key activity endpoint. Mean placebo-adjusted sweat chloride change was −1.0 mmol/L with p=0.7….
